The Effect of Recombinant Aminopeptidase A on Hypertension in Spontaneously Hypertensive Rats: Its Effect in Comparison with Candesartan

Abstract

An understanding of aminopeptidase A in hypertension is important, given its ability to cleave the N-terminal aspartic acid of potent vasoconstrictor angiotensin II. However, the role of aminopeptidase A in hypertension has received limited attention. Because we have succeeded in producing recombinant human aminopeptidase A, the effect of aminopeptidase A on systolic blood pressure in the spontaneously hypertensive rat was examined. Aminopeptidase A of 0.016 mg/kg was administrated intravenously to spontaneously hypertensive rats and blood pressure was monitored for 72 h. For repeated administration, aminopeptidase A doses of 0.016 mg/kg and 0.1-mg/kg doses of candesartan (an angiotensin II receptor 1 subtype blocker) were administrated daily in spontaneously hypertensive rats and blood pressure was monitored for 5 d. Bolus intravenous injection of aminopeptidase A at a dose of 0.016 mg/kg significantly decreased systolic blood pressure for 36 h in spontaneously hypertensive rats. A comparison of the antihypertensive effects of aminopeptidase A versus candesartan in spontaneously hypertensive rats showed that the effective dose of aminopeptidase A was about one-tenth that of candesartan. These results suggest the novel approach of utilizing aminopeptidase A to treat hypertension by degrading circulating angiotensin II before it binds to the receptor 1 subtype.

Key words

angiotensin II - angiotensin III - angiotensin II receptor blockers - angiotensin-converting enzyme - mutant aminopeptidase A - renin-angiotensin system - Wistar–Kyoto rats

References

• 1 Raasch W, Johren O, Schwartz S, Gieselberg A, Dominiak P. Combined blockade of AT1-receptors and ACE synergistically potentiates antihypertensive effects in SHR.  J Hypertens. 2004;  22 611-618
• 2 Boschmann M, Kreuzberg U, Engeli S, Adams F, Franke G, Klaua S, Scholze J, Weidinger G, Luft FC, Sharma AM, Jordan J. The effect of oral glucose loads on tissue metabolism during angiotensin II receptor and beta-receptor blockade in obese hypertensive subjects.  Horm Metab Res. 2006;  38 323-329
• 3 Wong PC, Price Jr WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PB. Hypertensive action of Dup 753, an angiotensin II antagonist, in spontaneously hypertensive rats nonpeptide angiotensin II receptor antagonists: X.  Hypertension. 1990;  15 459-468
• 4 Huthinson JS, Mendelson FA, Doyle AE. Hypotensive action of captopril and saralasin in intact and anephric spontaneously hypertensive rats.  Hypertension. 1980;  2 119-124
• 5 Shindo K, Sokabe H. Renin-angiotensin system in spontaneously hypertensive rats.  Am J Physiol. 1976;  231 1295-1299
• 6 Guidi E, Hollenberg NK. Differential pressor and renal vascular reactivity to angiotensin II in spontaneously hypertensive and Wister-Kyoto rats.  Hypertension. 1987;  9 591-597
• 7 Chatziantoniou C, Daniels FH, Arendshorst WJ. Exaggerated renal vascular reactivity to angiotensin and thromboxane in young genetically hypertensive rats.  Am J Physiol. 1990;  259 F372-F382
• 8 Chatziantoniou C, Arendshorst WJ. Angiotensin and thromboxane in genetically hypertensive rats: Renal blood flow and receptor studies.  Am J Physiol. 1991;  261 F238-F247
• 9 Mizutani S, Okano K, Hasegawa E, Sakura H, Yamada M. Aminopeptidase A in human placenta.  Biochim Biophys Acta. 1981;  13 168-178
• 10 Mizutani S, Furuhashi M, Imaizumi H, Ito Y, Kurauchi O, Tomoda Y. Effects of human placental aminopeptidases in spontaneously hypertensive rats.  Med Sci Res. 1987;  15 1203-1204
• 11 Mitsui T, Nomura S, Okada M, Ohno Y, Kobayashi H, Nakashima Y, Murata Y, Takeuchi M, Kuno N, Nagasaka T, O-Wang J, Cooper MD, Mizutani S. Hypertension and angiotensin II hypersensitivity in aminopeptidase A-deficient mice.  Mol Med. 2003;  9 57-62
• 12 Goto Y, Hattori A, Ishii Y, Mizutani S, Tsujimoto M. Enzymatic properties of human aminopeptidase A: Regulation of its enzymatic activity by calcium and angiotensin IV.  J Biol Chem. 2006;  281 23503-23513
• 13 Nakashima Y, Ohno Y, Itakura A, Takeuchi M, Mutata Y, Kuno N, Mizutani S. Possible involvement of aminopeptidase A in hypertension in spontaneously hypertensive rats (SHRs) and change of refractoriness in response to angiotensin II in pregnant SHRs.  J Hypertens. 2002;  20 2233-2238
• 14 Vazeux G, Iturrioz X, Corvol P, Llorens-Cortes C. A glutamate residue contributes to the exopeptidase specificity in aminopeptidase A.  Biochem J. 1998;  1 407-413
• 15 Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats.  Jpn Cir J. 1963;  27 282-293
• 16 Penesova A, Cizmarova E, Kvetnansky R, Koska J, Sedlakova B, Krizanova O. Insertion/deletion polymorphism on ace gene is associated with endothelial dysfunction in young patients with hypertension.  Horm Metab Res. 2006;  38 592-597
• 17 Mizutani S, Akiyama H, Kurauchi O, Taira H, Narita O, Tomoda Y. In vitro degradation of angiotensin II (A-II) by human placental subcellular fractions, pregnancy sera and purified placental aminopeptidases.  Acta Endocrinol (Copenh). 1985;  110 135-139
• 18 Mizutani S, Yamada R, Kurauchi O, Ito Y, Narita O, Tomoda Y. Serum aminopeptidase A (AAP) in normal pregnancy and pregnancy complicated by pre-eclampsia.  Arch Gynecol. 1987;  240 27-31
• 19 Song L, Healy DP. Kidney aminopeptidase A and hypertension, part II effects of angiotensin II.  Hypertension. 1999;  33 746-752
• 20 Hariyama Y, Itakura A, Okamura M, Ito M, Murata Y, Nagasaka T, Mizutani S. Placental aminopeptidas A as a possible barrier of angiotensin II between mother and fetus.  Placenta. 2002;  21 621-627
• 21 Ino K, Uehara C, Kikkawa F, Kajiyama H, Shibata K, Suzuki T, Khin EE, Ito M, Takeuchi M, Itakura A, Mizutani S. Enhancement of aminopeptidase A expression during angiotensin II-induced choriocharcinoma cell proliferation through AT1 receptor involving protein kinase C-and mitogen-activated protein kinase-dependent signaling pathway.  J Clin Endocrinol Metab. 2003;  88 3973-3982
• 22 Kieback AG, Iven H, Stolzenburg K, Baumann G. Saterinone, dobutamine, and sodium nitroprusside: comparison of cardiovascular profiles in patients with congestive heart failure.  J Cardiovasc Pharmacol. 1998;  32 629-636

Correspondence